Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit

Published 06/01/2022, 08:38 AM
Updated 06/01/2022, 08:44 AM
© Reuters.

© Reuters.

By Geoffrey Smith 

Investing.com -- Pfizer (NYSE:PFE) will sell down its stake in Haleon, the consumer healthcare unit of GSK (LON:GSK), after its listing in London planned for later this month, GSK said on Wednesday.

That indicates a change of heart on the part of the U.S. pharma giant, which owns 32% of the group behind such brands as Voltaren joint pain cream and Sensodyne toothpaste. GSK had said earlier this year when it announced the spin-off plan, that Pfizer would hold on to its shares and have representation on its board.

The news creates an unwelcome stock hangover effect for GSK as it prepares for a deal that it hopes will lighten its balance sheet and sharpen its focus on cancer and immunology drugs. The U.K. company said, however, that Pfizer had agreed to reduce its stake in “a disciplined manner” under a marketing agreement with GSK, after a lockup period of “several months”.

Under the terms of the demerger plan, GSK will keep a stake of around 6% in Haleon for now but it intends to monetize that in due course, to fund its future investments in developing or buying new drugs. Another 7.5% stake will be held by mechanisms to support its pension plan, while GSK shareholders will receive shares accounting for just under 55% of the company.

Under pressure from activist investor Elliott Management, GSK chief executive Emma Walmsley has decided to shed the cash-generative but staid business to pursue the higher valuations typically enjoyed by companies that specialize in developing new drugs. Walmsley rejected an offer of 50 billion pounds ($63 billion) from Unilever (NYSE:UL) earlier this year as too low, stressing that it expects organic sales growth of between 4% and 6% in the medium term.

GSK's new focus was evident earlier this week in its acquisition of U.S.-based vaccine specialist Affinivax for up to $3.3 billion. It also agreed to pay $1.9 billion for Sierra Oncology (NASDAQ:SRRA) in April.

GSK stock was up 0.1% by 8:40 AM ET (1240 GMT) in London trading, while Pfizer stock was up 0.2%.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.